Released : January 21, 2021 14:49 RNS Number : 5100M MaxCyte, Inc. 21 January 2021 MaxCyte, Inc. ("MaxCyte" or the "Company") Increase to Block Listing, Block Listing Return and Total Voting Rights MaxCyte (LSE: MXCT, MXCS), the global cell-based medicines and life
Released : January 20, 2021 07:00 RNS Number : 2360M MaxCyte, Inc. 20 January 2021 MaxCyte, Inc. ("MaxCyte" or the "Company") Trading Update · Full-year revenues at $26.2m (21% growth over FY 2019) and second half revenue at $15.3m (15% over
Myeloid to utilize MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to advance its novel cell therapies to treat solid tumors, T cell lymphoma and glioblastoma CAMBRIDGE, MA and GAITHERSBURG, MD, January 11, 2021 — Myeloid Therapeutics, Inc., a company harnessing and reprogramming
Released : January 11, 2021 07:00 RNS Number : 1564L MaxCyte, Inc. 11 January 2021 Myeloid Therapeutics and MaxCyte Enter Clinical and Commercial Licensing Agreement to Advance Myeloid's Cell Therapy Programs Myeloid to utilize MaxCyte's Flow Electroporation ® technology and ExPERT ™
Released : December 23, 2020 07:00 RNS Number : 6024J MaxCyte, Inc. 23 December 2020 TRADING UPDATE MaxCyte to exceed 2020 Full Year market expectations Gaithersburg, Maryland - 23 December 2020: MaxCyte (LSE: MXCT, MXCL), a global cell-based therapies and life sciences company, today
Released : November 09, 2020 13:00 RNS Number : 6703E MaxCyte, Inc. 09 November 2020 CARMA Cell Therapies™ to Share Results of In-vitro Characterization of MCY-M11 at SITC 2020 Annual Meeting Gaithersburg, Maryland - 9 November 2020: MaxCyte, Inc.
Released : November 09, 2020 07:00 RNS Number : 5929E MaxCyte, Inc. 09 November 2020 MaxCyte to Present at Two Upcoming Virtual Healthcare Investor Conferences Gaithersburg, MD , 9 November 2020: MaxCyte, Inc. (LSE: MXCT, MXCL), a global cell-based therapies and life sciences
Released : November 02, 2020 15:52 RNS Number : 9956D MaxCyte, Inc. 02 November 2020 Result of AGM Gaithersburg, Maryland - 02 November 2020: MaxCyte (LSE: MXCT, MXCL), a global cell-based therapies and life sciences company, announces that at its Annual General Meeting held on 30
Released : October 22, 2020 18:22 RNS Number : 9790C MaxCyte, Inc. 22 October 2020 Disclosure of Remuneration for Non-Audit Services Gaithersburg, Maryland - 22 October 2020: MaxCyte, Inc. (LSE: MXCT, MXCL), a global cell-based therapies and life sciences company, today announces an
Released : October 14, 2020 07:00 RNS Number : 9794B MaxCyte, Inc. 14 October 2020 Notification of Annual General Meeting and Declaration of Audit Remuneration Gaithersburg, Maryland - 14 October 2020: MaxCyte, Inc. (LSE: MXCT, MXCL), a global cell-based therapies and life sciences
